Pasithea Therapeutics Corp.
KTTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001841330
No open-market purchases or sales by Pasithea Therapeutics Corp. insiders were filed in the last 90 days; 25 institutions reported holding it in 13F filings for Q2 2026, worth $8.66M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Pasithea Therapeutics Corp. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 4 | 7 | +3 |
| Shares | 415.6K | 614.3K | +198.8K (+47.8%) |
| Value | $1.26M | $1.09M | −$178.0K (−14.1%) |
New holders (6)
Institutions that held Pasithea Therapeutics Corp. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| K2 Principal Fund, L.P. | 550,000 | $973.0K | 0.12% |
| Vanguard Group Inc | 12,700 | $22.0K | 0.00% |
| HRT Financial LP | 12,731 | $22.0K | 0.00% |
| BlackRock Inc. | 8,502 | $15.0K | 0.00% |
| JPMorgan Chase & Co | 1,000 | $2.00K | 0.00% |
| Wells Fargo & Company | 30 | $0 | 0.00% |
Sold out (3)
Institutions that held Pasithea Therapeutics Corp. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Kepos Capital LP | 400,000 | $1.22M |
| Two Sigma Securities, LLC | 10,440 | $32.0K |
| UBS Group AG | 3,290 | $10.0K |